3,4'-Dipiperidin | 116595-12-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3,4'-Dipiperidin
• 英文别名: epi-3,4'-Dipiperidin；dodecahydro-[3,4']bipyridinyl；Dodecahydro-[3,4']bipyridyl；3-(Piperidin-4-YL)piperidine；3-piperidin-4-ylpiperidine
• CAS: 116595-12-1
• 化学式: C₁₀H₂₀N₂
• 分子量: 168.282
• InChiKey: XYHYGLGHYZQJBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 、 platinum(IV) oxide 作用下， 生成 3,4'-Dipiperidin
  参考文献：
  名称：

  Smith, Journal of the American Chemical Society, 1928, vol. 50, p. 1937

  摘要：

  DOI：

文献信息

• Interfacially polymerized, bipiperidine-polyamide membranes for reverse osmosis and/or nanofiltration and process for making the same
  申请人：HYDRANAUTICS

  公开号：EP1060785A1

  公开（公告）日：2000-12-20

  Selective, water-permeable membranes for reverse osmosis and nanofiltration are prepared by interfacially polymerizing on a microporous support an essentially monomeric bipiperidine reactant, and an essentially monomeric amine-reactive polyfunctional aromatic or cycloaliphatic acyl halide having on the average at least about 2 acyl halide groups per reactant molecule. The polymerization is optionally carried out in the presence of a monomeric amine salt, which can increase the flux rate of the resulting membrane.

  用于反渗透和纳滤的选择性透水膜的制备方法是在微孔载体上将基本上是单体的双哌啶反应物和基本上是单体的胺反应性多官能团芳香族或环脂族酰基卤进行界面聚合，每个反应物分子平均至少具有约 2 个酰基卤基团。聚合可选择在有单体胺盐存在的情况下进行，这样可以提高所得膜的通量。
• NOVEL COMPOUNDS
  申请人：GlaxoSmithKline S.p.A.

  公开号：EP1339691A1

  公开（公告）日：2003-09-03
• US5215967A
  申请人：——

  公开号：US5215967A

  公开（公告）日：1993-06-01
• US6464873B1
  申请人：——

  公开号：US6464873B1

  公开（公告）日：2002-10-15
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXOSMITHKLINE SPA

  公开号：WO2002044154A1

  公开（公告）日：2002-06-06

  Certain compounds of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof, wherein R1 is H or alkyl; R2 is R8R9; R8 is a single bond or alkyl, optionally substituted one or more times by hydroxy; R9 is aryl or cycloalkyl or heteroaryl, optionally substituted one or more times by hydroxy, alkoxy ou alkoxyalkyl; R3 is H or alkyl or cycloalkyl or cycloalkylalkyl, optionally substituted one or more times by hydroxy or by one or more fluorines; R4 is NR10R11; R10 and R11 Are independently selected from H or alkyl, or R10 and R11 together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic ring comprising 3-8 ring menbers, which heterocyclic ring is unsubstituted or is substituted one or more times by one or more substituents R12; R12 is oxo or R13R14R15, wherein R13 Is a single bond or alkyl, R14 is OC(O) or C(O)O, and R15 is H or alkyl; R5 is an alkyl, cycloalkyl, cycloalkylalkyl, aryl or single or fused ring aromatic heterocyclic group, which group is unsubstituted or is substituted one or more times by one or more substituents selected from halo such as fluoro, alkyl or haloalkyl such as fluoroalkyl; R6 represents H or up to three substituents independently selected from the list consisting of: alkyl, alkenyl, aryl, alkoxy or a hydroxylated derivative thereof, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, alkoxycarbonyl, haloalkyl such as trifluoromethyl, acyloxy, amino, mono- or di- alkylamino, alkoxyamido, alkoxycarboxylate or an esterified derivative thereof; R7 is H or halo; a is 1-6; and any of R1, R3, R5, R8, R10, R11 and R12 May optionally be substituted one or more times by halo, hydroxy, amino, cyano, nitro, carboxy or oxo; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.